SYNERGYS BIOTHERAPEUTICS, INC.
Walnut Creek, CA · Biotech · Defunct
EEPA125, an antibody-fusion protein combining anti-EGFR monoclonal antibody with an engineered endostatin variant to inhibit angiogenesis and vasculogenic mimicry in triple-negative breast cancer
synergysbio.com →- Grants
- $1.0M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer using Antibody Fusion Protein | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer | $400,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3364 | AVICANNA INC. | — | $10M |
| 3365 | Adipo Therapeutics, LLC | — | $6.0M |
| 3366 | Adcendo | — | — |
| 3367 | SYNERGYS BIOTHERAPEUTICS, INC. | — | — |
| 3368 | COLLABORATIONS PHARMACEUTICALS INC | — | — |
| 3369 | Centivax Inc | — | — |
| 3370 | SPERAGEN, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.